These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30690502)

  • 1. Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder.
    Shi Z; Jagannathan K; Wang AL; Fairchild VP; Lynch KG; Suh JJ; Childress AR; Langleben DD
    Int J Neuropsychopharmacol; 2019 Mar; 22(3):180-185. PubMed ID: 30690502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
    Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
    Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
    Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
    Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
    Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
    J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.
    Sullivan MA; Bisaga A; Pavlicova M; Carpenter KM; Choi CJ; Mishlen K; Levin FR; Mariani JJ; Nunes EV
    Am J Psychiatry; 2019 Feb; 176(2):129-137. PubMed ID: 30336703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.
    Gordon MS; Vocci FJ; Fitzgerald TT; O'Grady KE; O'Brien CP
    Contemp Clin Trials; 2017 Feb; 53():130-136. PubMed ID: 28011389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
    Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.
    Everly JJ; DeFulio A; Koffarnus MN; Leoutsakos JM; Donlin WD; Aklin WM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Addiction; 2011 Jul; 106(7):1309-18. PubMed ID: 21320227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone: Not Just for Opioids Anymore.
    Sudakin D
    J Med Toxicol; 2016 Mar; 12(1):71-5. PubMed ID: 26546222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
    Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Boney TY; Hoskinson RA; Wilson D; McDonald R; Rotrosen J; Gourevitch MN; Gordon M; Fishman M; Chen DT; Bonnie RJ; Cornish JW; Murphy SM; O'Brien CP
    N Engl J Med; 2016 Mar; 374(13):1232-42. PubMed ID: 27028913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
    Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
    Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
    Coviello DM; Cornish JW; Lynch KG; Boney TY; Clark CA; Lee JD; Friedmann PD; Nunes EV; Kinlock TW; Gordon MS; Schwartz RP; Nuwayser ES; O'Brien CP
    Subst Abus; 2012; 33(1):48-59. PubMed ID: 22263713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.